[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100415606":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":33,"locations":43,"responsibleParty":62,"collaborators":64,"id":68,"slug":38,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":38,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":38,"enrollmentInfo":76,"targetDuration":38,"studyType":79,"phases":80,"briefSummary":83,"conditions":84,"keywords":38,"overallStatus":46,"whyStopped":38,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Abramson Cancer Center at Penn Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Atezolizumab and Tocilizumab","EXPERIMENTAL","Participants receive Atezolizumab 1200mg IV and Tocilizumab 6mg\u002Fkg IV (or Tocilizumab 4mg\u002Fkg IV) every 21 days",[13,14],"Drug: Atezolizumab","Drug: Tocilizumab",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Atezolizumab","1200mg infusion",[9],[22],"Tecentriq",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Tocilizumab","Tocilizumab 6mg\u002Fkg or 4mg\u002Fkg infusion",[9],[28],"Actemra, RoActemra, RO4877533",[30],{"name":31,"affiliation":5,"role":32},"Melina Marmarelis, MD, MSCE","PRINCIPAL_INVESTIGATOR",[34,40],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Melissa Volpe, BA","CONTACT","215-220-9703",null,"melissa.volpe@pennmedicine.upenn.edu",{"name":31,"role":36,"phone":41,"phoneExt":38,"email":42},"215-615-5835","melina.marmarelis@pennmedicine.upenn.edu",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Abramson Cancer Center of the University of Pennsylvania","RECRUITING","Philadelphia","Pennsylvania","19104","United States",{"type":52,"coordinates":53},"Point",[54,55],-75.16362,39.95238,{"lat":55,"lon":54},[58,61],{"name":59,"role":36,"phone":37,"phoneExt":38,"email":60},"Mel V, BA","Melissa.volpe@pennmedicine.upenn.edu",{"name":31,"role":32,"phone":38,"phoneExt":38,"email":38},{"type":63,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR",[65],{"name":66,"class":67},"Genentech, Inc.","INDUSTRY","100415606",false,"NCT04691817","Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy","A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy","Inclusion Criteria:\n\n* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older\n* Prior exposure to at least 1 line of therapy\n* Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial\n* ECOG PS 0-2\n\nExclusion Criteria:\n\n* Presence of a driver mutation that is susceptible to targeted therapy\n* No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy\n* Other active invasive malignancy requiring ongoing therapy\n* Evidence of progressing or untreated brain metastases\n* Evidence or history of leptomeningeal disease\n* Uncontrolled tumor related pain\n* History of an autoimmune disease or IPF","ALL","18 Years",{"count":77,"type":78},28,"ESTIMATED","INTERVENTIONAL",[81,82],"PHASE1","PHASE2","This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.",[85],"Lung Cancer, Nonsmall Cell","2026-01-06",{"date":88,"type":89},"2026-01-07","ACTUAL",{"date":91,"type":89},"2023-07-25",{"date":93,"type":78},"2027-09",{"name":5,"class":6},1]